Company Description

Simmpyra Pharmaceuticals is developing Simmpyra-1 and -2 are two patent-pending novel drug candidates designed to treat triple-negative breast cancer. These drugs efficiently kill TNBC cells without causing any toxicity in normal mammary epithelial cells and regress human TNBC tumors in a PDX humanized mouse model. Both Simmpyra-1 & -2 are 1000-times more potent inhibitors of STAT3 compared to known STAT3 inhibitors.